Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin/laropiprant added to statin therapy in coronary heart disease
2009-017622-39Phase 4Completed
- Sponsor
- University Medical Centre Ljubljana
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary arteriosclerosis comparing ER niacin + laropiprant with Placebo (2 arms). Primary endpoint: Endothelial dependent dilatation of the arterial wall after 12 weeks. Started Apr 2010; status: completed.
02
Drugs
niacinlaropiprant
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2009-017622-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017622-39.